Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Bactericidal Activity of Meropenem + Amoxicillin/Clavulanate With or Without Rifampin in Pulmonary TB
NCT03174184Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Aug 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifampicin, meropenem, amoxicillin + clavulanate in pulmonary tuberculosis (TB), sponsored by Johns Hopkins University. Started Aug 2017; status: completed.
02
Drugs
rifampicinmeropenemamoxicillin + clavulanate
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03174184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174184.